María Gómez-Martín, Oliver J Canfell, Li Kheng Chai, Anna K Jansson, Robyn Littlewood, Clair Sullivan, Dawn Power, Erin D Clarke, Louisa Ells, Nienke De Vlieger, Tracy L Burrows, Clare E Collins
{"title":"在一个有效药物的时代，初级预防肥胖的作用是什么？","authors":"María Gómez-Martín, Oliver J Canfell, Li Kheng Chai, Anna K Jansson, Robyn Littlewood, Clair Sullivan, Dawn Power, Erin D Clarke, Louisa Ells, Nienke De Vlieger, Tracy L Burrows, Clare E Collins","doi":"10.1007/s13679-025-00632-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review.</p><p><strong>Recent findings: </strong>Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (> 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment. Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.</p>","PeriodicalId":10846,"journal":{"name":"Current Obesity Reports","volume":"14 1","pages":"39"},"PeriodicalIF":9.5000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058953/pdf/","citationCount":"0","resultStr":"{\"title\":\"What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?\",\"authors\":\"María Gómez-Martín, Oliver J Canfell, Li Kheng Chai, Anna K Jansson, Robyn Littlewood, Clair Sullivan, Dawn Power, Erin D Clarke, Louisa Ells, Nienke De Vlieger, Tracy L Burrows, Clare E Collins\",\"doi\":\"10.1007/s13679-025-00632-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review.</p><p><strong>Recent findings: </strong>Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (> 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment. Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.</p>\",\"PeriodicalId\":10846,\"journal\":{\"name\":\"Current Obesity Reports\",\"volume\":\"14 1\",\"pages\":\"39\"},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058953/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Obesity Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13679-025-00632-0\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Obesity Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13679-025-00632-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?
Purpose of review: To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review.
Recent findings: Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (> 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment. Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.
期刊介绍：
The main objective of Current Obesity Reports is to provide expert review articles on recent advancements in the interdisciplinary field of obesity research. Our aim is to offer clear, insightful, and balanced contributions that will benefit all individuals involved in the treatment and prevention of obesity, as well as related conditions such as cardiovascular diseases, endocrine disorders, gynecological issues, cancer, mental health, respiratory complications, and rheumatological diseases. We strive to redefine the way knowledge is expressed and provide organized content for the benefit of our readership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
